JP2006521319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006521319A5 JP2006521319A5 JP2006504792A JP2006504792A JP2006521319A5 JP 2006521319 A5 JP2006521319 A5 JP 2006521319A5 JP 2006504792 A JP2006504792 A JP 2006504792A JP 2006504792 A JP2006504792 A JP 2006504792A JP 2006521319 A5 JP2006521319 A5 JP 2006521319A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- alkyl
- compound
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 28
- 239000001257 hydrogen Substances 0.000 claims 28
- -1 monosubstituted phenyl Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 229910052736 halogen Inorganic materials 0.000 claims 21
- 150000002367 halogens Chemical class 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 15
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- 125000004663 dialkyl amino group Chemical group 0.000 claims 15
- 125000003282 alkyl amino group Chemical group 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 10
- 125000004995 haloalkylthio group Chemical group 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 9
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 9
- 125000002252 acyl group Chemical group 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 125000001153 fluoro group Chemical group F* 0.000 claims 8
- 230000008878 coupling Effects 0.000 claims 7
- 238000010168 coupling process Methods 0.000 claims 7
- 238000005859 coupling reaction Methods 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 150000001502 aryl halides Chemical class 0.000 claims 4
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 claims 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 150000002825 nitriles Chemical class 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical compound O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 150000003573 thiols Chemical class 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 102100034343 Integrase Human genes 0.000 claims 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000011260 aqueous acid Substances 0.000 claims 2
- 150000001543 aryl boronic acids Chemical class 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 229960005319 delavirdine Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960003804 efavirenz Drugs 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960000689 nevirapine Drugs 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- FFSJPOPLSWBGQY-UHFFFAOYSA-N triazol-4-one Chemical compound O=C1C=NN=N1 FFSJPOPLSWBGQY-UHFFFAOYSA-N 0.000 claims 2
- XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 claims 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 claims 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical class [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 229960001830 amprenavir Drugs 0.000 claims 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims 1
- 125000005604 azodicarboxylate group Chemical group 0.000 claims 1
- 230000031709 bromination Effects 0.000 claims 1
- 238000005893 bromination reaction Methods 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 1
- 238000006555 catalytic reaction Methods 0.000 claims 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 229960002656 didanosine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229940125777 fusion inhibitor Drugs 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims 1
- 150000007857 hydrazones Chemical class 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 229960001936 indinavir Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 229960004525 lopinavir Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229960000884 nelfinavir Drugs 0.000 claims 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
- LNWHCOPMPXKPNZ-UHFFFAOYSA-N o-methyl n-aminocarbamothioate Chemical compound COC(=S)NN LNWHCOPMPXKPNZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 229960001852 saquinavir Drugs 0.000 claims 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical group C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 229960001203 stavudine Drugs 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229940054565 sustiva Drugs 0.000 claims 1
- XWMXMWHHTIEXRE-UHFFFAOYSA-N thiadiazole 1-oxide Chemical compound O=S1C=CN=N1 XWMXMWHHTIEXRE-UHFFFAOYSA-N 0.000 claims 1
- 229940098802 viramune Drugs 0.000 claims 1
- 229960002555 zidovudine Drugs 0.000 claims 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 1
- 0 *c1c(*)c(I)c(*)c(*)c1CC(*C1OC1N)=* Chemical compound *c1c(*)c(I)c(*)c(*)c1CC(*C1OC1N)=* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45713003P | 2003-03-24 | 2003-03-24 | |
| US60/457,130 | 2003-03-24 | ||
| PCT/EP2004/002995 WO2004085411A1 (en) | 2003-03-24 | 2004-03-22 | Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006521319A JP2006521319A (ja) | 2006-09-21 |
| JP2006521319A5 true JP2006521319A5 (https=) | 2007-05-17 |
| JP4708329B2 JP4708329B2 (ja) | 2011-06-22 |
Family
ID=33098199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504792A Expired - Lifetime JP4708329B2 (ja) | 2003-03-24 | 2004-03-22 | Ｈｉｖ介在疾患を治療するための非ヌクレオシド系逆転写酵素阻害剤ｉ |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7208509B2 (https=) |
| EP (1) | EP1608633B1 (https=) |
| JP (1) | JP4708329B2 (https=) |
| KR (1) | KR101122456B1 (https=) |
| CN (1) | CN100588650C (https=) |
| AR (1) | AR043673A1 (https=) |
| AU (1) | AU2004224153B2 (https=) |
| BR (2) | BRPI0408767B8 (https=) |
| CA (1) | CA2518437C (https=) |
| CL (1) | CL2004000590A1 (https=) |
| CO (1) | CO5601029A2 (https=) |
| ES (1) | ES2574580T3 (https=) |
| HR (1) | HRP20050830A2 (https=) |
| IL (1) | IL170343A (https=) |
| MX (1) | MXPA05010210A (https=) |
| NO (1) | NO334095B1 (https=) |
| NZ (1) | NZ541829A (https=) |
| RU (1) | RU2342367C2 (https=) |
| TW (1) | TW200505441A (https=) |
| WO (1) | WO2004085411A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ550857A (en) * | 2004-04-01 | 2009-12-24 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-ones as PPAR delta modulators |
| US8293778B2 (en) | 2004-07-27 | 2012-10-23 | Roche Palo Alto Llc | Heterocyclic antiviral compounds |
| WO2006010545A1 (en) * | 2004-07-27 | 2006-02-02 | F. Hoffmann-La Roche Ag | Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors |
| CN101180280A (zh) * | 2005-03-24 | 2008-05-14 | 弗·哈夫曼-拉罗切有限公司 | 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物 |
| AR057455A1 (es) | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| JP2009510013A (ja) * | 2005-09-30 | 2009-03-12 | エフ．ホフマン−ラ ロシュ アーゲー | Ｎｎｒｔ阻害剤 |
| WO2007045573A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
| ATE545637T1 (de) * | 2005-12-15 | 2012-03-15 | Astrazeneca Ab | Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen |
| SG183007A1 (en) | 2006-07-07 | 2012-08-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
| CL2007002105A1 (es) * | 2006-07-21 | 2008-02-22 | Hoffmann La Roche | Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u |
| CA2658984C (en) * | 2006-08-16 | 2014-12-02 | Joshua Kennedy-Smith | Non-nucleoside reverse transcriptase inhibitors |
| TW200831085A (en) * | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
| PL3150586T3 (pl) * | 2007-02-23 | 2020-06-01 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
| MX2009010932A (es) * | 2007-04-09 | 2009-10-29 | Hoffmann La Roche | Inhibidores no nucleosidos de transcriptasa inversa. |
| BRPI0811645A2 (pt) | 2007-05-30 | 2014-11-11 | Hoffmann La Roche | Inibidores de transcriptase reversa de não-nucleosídeo |
| BRPI0811988B1 (pt) * | 2007-05-30 | 2021-05-25 | F. Hoffmann-La Roche Ag | Composto intermediário e processo para preparação de triazolonas |
| WO2008157273A1 (en) * | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
| WO2008157330A1 (en) * | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
| EP2170836A1 (en) * | 2007-06-22 | 2010-04-07 | F. Hoffmann-Roche AG | Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors |
| US8492415B2 (en) * | 2007-07-03 | 2013-07-23 | Yale University | Azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV) |
| RU2495878C2 (ru) * | 2007-12-21 | 2013-10-20 | Ф.Хоффманн-Ля Рош Аг | Гетероциклические антивирусные соединения |
| SI2924034T1 (sl) * | 2010-03-30 | 2017-05-31 | Merck Canada Inc. | Farmacevtski sestavek, ki obsega nenukleozidni inhibitor reverzne transkriptaze |
| CU23896B1 (es) * | 2010-04-01 | 2013-05-31 | Ct De Ingeniería Genética Y Biotecnología | Método para inhibir la replicación del vih en células de mamíferos |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| CN104230929B (zh) * | 2013-06-19 | 2015-11-18 | 华东师范大学 | 一种非核苷类hiv-1反转录酶抑制剂 |
| WO2015153304A1 (en) | 2014-04-01 | 2015-10-08 | Merck Sharp & Dohme Corp. | Prodrugs of hiv reverse transcriptase inhibitors |
| WO2026042788A1 (ja) * | 2024-08-20 | 2026-02-26 | 塩野義製薬株式会社 | 複素環誘導体 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3274185A (en) | 1963-10-08 | 1966-09-20 | S E Massengill Company | Phthalazine derivatives |
| US3813384A (en) | 1972-01-17 | 1974-05-28 | Asta Werke Ag Chem Fab | Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof |
| JP2593084B2 (ja) | 1986-12-19 | 1997-03-19 | メレルダウファーマスーティカルズ インコーポレーテッド | ５−アリールー３ｈ−１，２，４−トリアゾールー３−オン類の神経変性障害の処置への用途 |
| PH24094A (en) | 1986-12-19 | 1990-03-05 | Merrell Dow Pharma | 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants |
| US5436252A (en) | 1986-12-19 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders |
| US4942236A (en) | 1987-09-30 | 1990-07-17 | American Home Products Corporation | 2-aryl substituted pyridyl-containing phenyl sulfonamido compounds as antiallergic and antiinflammatory agents |
| US5103014A (en) | 1987-09-30 | 1992-04-07 | American Home Products Corporation | Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives |
| US4826990A (en) | 1987-09-30 | 1989-05-02 | American Home Products Corporation | 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
| US4966909A (en) | 1989-12-20 | 1990-10-30 | Merrell Dow Pharmaceuticals | 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants |
| US5331002A (en) | 1990-04-19 | 1994-07-19 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers |
| US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
| US5641796A (en) | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| WO1997040017A2 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| TW467902B (en) | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| PL223343B1 (pl) * | 2000-10-30 | 2016-10-31 | Kudos Pharm Ltd | Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe |
| UA82048C2 (uk) | 2000-11-10 | 2008-03-11 | Эли Лилли Энд Компани | Агоністи альфа-рецепторів, активованих проліфератором пероксисом |
| JP2002275165A (ja) * | 2001-01-12 | 2002-09-25 | Sumitomo Pharmaceut Co Ltd | トリアゾール誘導体 |
-
2004
- 2004-03-18 TW TW093107292A patent/TW200505441A/zh unknown
- 2004-03-22 AU AU2004224153A patent/AU2004224153B2/en not_active Expired
- 2004-03-22 BR BRPI0408767A patent/BRPI0408767B8/pt not_active IP Right Cessation
- 2004-03-22 ES ES04722259.1T patent/ES2574580T3/es not_active Expired - Lifetime
- 2004-03-22 MX MXPA05010210A patent/MXPA05010210A/es active IP Right Grant
- 2004-03-22 JP JP2006504792A patent/JP4708329B2/ja not_active Expired - Lifetime
- 2004-03-22 NZ NZ541829A patent/NZ541829A/en unknown
- 2004-03-22 CA CA2518437A patent/CA2518437C/en not_active Expired - Lifetime
- 2004-03-22 RU RU2005132632/04A patent/RU2342367C2/ru active
- 2004-03-22 CN CN200480006480A patent/CN100588650C/zh not_active Expired - Lifetime
- 2004-03-22 CL CL200400590A patent/CL2004000590A1/es unknown
- 2004-03-22 HR HR20050830A patent/HRP20050830A2/xx not_active Application Discontinuation
- 2004-03-22 AR ARP040100937A patent/AR043673A1/es not_active Application Discontinuation
- 2004-03-22 KR KR1020057017771A patent/KR101122456B1/ko not_active Expired - Lifetime
- 2004-03-22 BR BR122016023941-1A patent/BR122016023941B1/pt active IP Right Grant
- 2004-03-22 EP EP04722259.1A patent/EP1608633B1/en not_active Expired - Lifetime
- 2004-03-22 WO PCT/EP2004/002995 patent/WO2004085411A1/en not_active Ceased
- 2004-03-23 US US10/807,766 patent/US7208509B2/en not_active Expired - Lifetime
-
2005
- 2005-08-18 IL IL170343A patent/IL170343A/en active IP Right Grant
- 2005-09-15 NO NO20054264A patent/NO334095B1/no unknown
- 2005-09-21 CO CO05095661A patent/CO5601029A2/es not_active Application Discontinuation
-
2007
- 2007-02-02 US US11/701,881 patent/US7348345B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006521319A5 (https=) | ||
| RU2005132632A (ru) | Нуклеозидные ингибиторы i обратной транскриптазы, предназначенные для лечения заболеваний, опосредованных вич | |
| TWI519515B (zh) | Ｂ型肝炎抗病毒劑 | |
| RU2005132630A (ru) | Бензилпиридазиноны, как ингибиторы обратной транскриптазы | |
| US20200140398A1 (en) | Human helicase ddx3 inhibitors as therapeutic agents | |
| US20250312345A1 (en) | Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use | |
| EP3286178A1 (en) | Amino-substituted heterocyclic derivatives as sodium channel inhibitors | |
| EP1551828A1 (en) | Pyrazole derivatives | |
| US12540136B2 (en) | Pyrrolopyridine derivative and use thereof | |
| CN114846004B (zh) | 抗疟药 | |
| WO2004029042A1 (en) | Pyrazole derivatives as reverse transcriptase inhibitors | |
| US20240092759A1 (en) | Non-Covalent Inhibitors of the Main Protease of SARS-CoV-2 and Methods of Use | |
| ES2305563T3 (es) | Derivados de pirazol y su uso como agentes terapeuticos para enfermedades mediadas por el vih. | |
| RU2815649C1 (ru) | Пирролопиридиновое производное и его применение | |
| BR112017017229B1 (pt) | Composto, composto para uso médico ou na preparação de um medicamento e composição farmacêutica | |
| EP3224253A1 (en) | Bis(sulfonamide) derivatives and their use as mpges inhibitors |